StockData
Solid Biosciences Inc. logo

Solid Biosciences Inc. (SLDB) stock

SLDBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$6.44+0.09 (+1.42%)

Close on Nov 19, 2026Market cap $690.53MP/E –Yield –

Solid Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Solid Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$187.81M. For fiscal 2025 it was -$157.44M. The highest annual figure on record is -$20.51M in fiscal 2016.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$157.44M–
FY2024Dec 31, 2024-$100.67M–
FY2023Dec 31, 2023-$95.70M–
FY2022Dec 31, 2022-$100.99M–
FY2021Dec 31, 2021-$79.05M–
FY2020Dec 31, 2020-$57.50M–
FY2019Dec 31, 2019-$97.10M–
FY2018Dec 31, 2018-$77.97M–
FY2017Dec 31, 2017-$45.50M–
FY2016Dec 31, 2016-$20.51M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$52.74M–
Q1 FY2026Mar 31, 2026-$47.40M–
Q4 FY2025Dec 31, 2025-$54.12M–
Q3 FY2025Sep 30, 2025-$33.56M–
Q2 FY2025Jun 30, 2025-$37.79M–
Q1 FY2025Mar 31, 2025-$31.98M–
Q4 FY2024Dec 31, 2024-$29.85M–
Q3 FY2024Sep 30, 2024-$23.72M–
Q2 FY2024Jun 30, 2024-$21.75M–
Q1 FY2024Mar 31, 2024-$25.34M–
Q4 FY2023Dec 31, 2023-$20.91M–
Q3 FY2023Sep 30, 2023-$18.28M–
Q2 FY2023Jun 30, 2023-$28.00M–
Q1 FY2023Mar 31, 2023-$28.50M–
Q4 FY2022Dec 31, 2022-$35.34M–
Q3 FY2022Sep 30, 2022-$21.27M–
Q2 FY2022Jun 30, 2022-$17.01M–
Q1 FY2022Mar 31, 2022-$27.37M–
Q4 FY2021Dec 31, 2021-$21.53M-1826.9%
Q3 FY2021Sep 30, 2021-$18.66M–
Q2 FY2021Jun 30, 2021-$17.45M–
Q1 FY2021Mar 31, 2021-$21.40M–
Q4 FY2020Dec 31, 2020$1.25M–
Q3 FY2020Sep 30, 2020-$15.64M–
Q2 FY2020Jun 30, 2020-$13.15M–
Q1 FY2020Mar 31, 2020-$29.96M–
Q4 FY2019Dec 31, 2019-$21.89M–
Q3 FY2019Sep 30, 2019-$19.89M–
Q2 FY2019Jun 30, 2019-$27.44M–
Q1 FY2019Mar 31, 2019-$27.88M–
Q4 FY2018Dec 31, 2018-$22.84M–
Q3 FY2018Sep 30, 2018-$17.41M–
Q2 FY2018Jun 30, 2018-$19.55M–
Q1 FY2018Mar 31, 2018-$18.17M–
Q4 FY2017Dec 31, 2017-$14.31M–
Q3 FY2017Sep 30, 2017-$11.10M–
Q2 FY2017Jun 30, 2017-$9.65M–
Q1 FY2017Mar 31, 2017-$10.44M–

More Solid Biosciences figures

See a number that looks wrong?